7a29 › Citations

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.

<div class='caption-title'>Selection of sybodies against SARS-CoV-2 RBD.</div>
<div class='caption-title'>Biophysical characterization of identified sybodies.</div>
<div class='caption-title'>Sb23 neutralizes SARS-CoV-2 pseudoviruses and competes with ACE2.</div>
Custódio TF, Das H, Sheward DJ, Hanke L, Pazicky S, Pieprzyk J, Sorgenfrei M, Schroer MA, Gruzinov AY, Jeffries CM, Graewert MA, Svergun DI, Dobrev N, Remans K, Seeger MA, McInerney GM, Murrell B, Hällberg BM, Löw C
OpenAccess logo Nat Commun 11 5588 (2020)
Cited: 102 times
EuropePMC logo PMID: 33149112

Abstract

The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Therapeutic neutralizing antibodies constitute a key short-to-medium term approach to tackle COVID-19. However, traditional antibody production is hampered by long development times and costly production. Here, we report the rapid isolation and characterization of nanobodies from a synthetic library, known as sybodies (Sb), that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Several binders with low nanomolar affinities and efficient neutralization activity were identified of which Sb23 displayed high affinity and neutralized pseudovirus with an IC50 of 0.6 µg/ml. A cryo-EM structure of the spike bound to Sb23 showed that Sb23 binds competitively in the ACE2 binding site. Furthermore, the cryo-EM reconstruction revealed an unusual conformation of the spike where two RBDs are in the 'up' ACE2-binding conformation. The combined approach represents an alternative, fast workflow to select binders with neutralizing activity against newly emerging viruses.

Reviews - 7a29 mentioned but not cited (4)

  1. Monoclonal antibody therapies against SARS-CoV-2. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Lancet Infect Dis 22 e311-e326 (2022)
  2. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Valdez-Cruz NA, García-Hernández E, Espitia C, Cobos-Marín L, Altamirano C, Bando-Campos CG, Cofas-Vargas LF, Coronado-Aceves EW, González-Hernández RA, Hernández-Peralta P, Juárez-López D, Ortega-Portilla PA, Restrepo-Pineda S, Zelada-Cordero P, Trujillo-Roldán MA. Microb Cell Fact 20 88 (2021)
  3. Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Du L, Yang Y, Zhang X, Li F. Nanoscale 14 1054-1074 (2022)
  4. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2. Tang Q, Owens RJ, Naismith JH. Viruses 13 2214 (2021)

Articles - 7a29 mentioned but not cited (13)



Reviews citing this publication (31)

  1. SARS-CoV-2 Antiviral Therapy. Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. Clin Microbiol Rev 34 e0010921 (2021)
  2. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Finkelstein MT, Mermelstein AG, Parker Miller E, Seth PC, Stancofski ED, Fera D. Viruses 13 134 (2021)
  3. Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments. Arbabi-Ghahroudi M. Int J Mol Sci 23 5009 (2022)
  4. Recent review of COVID-19 management: diagnosis, treatment and vaccination. Chavda VP, Vuppu S, Mishra T, Kamaraj S, Patel AB, Sharma N, Chen ZS. Pharmacol Rep 74 1120-1148 (2022)
  5. Prospects of Neutralizing Nanobodies Against SARS-CoV-2. Chen F, Liu Z, Jiang F. Front Immunol 12 690742 (2021)
  6. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, Salomon S, Wood EM, So-Osman C, McQuilten Z, Spinner CD, Malin JJ, Stegemann M, Skoetz N, Kreuzberger N. Cochrane Database Syst Rev 6 CD014945 (2022)
  7. Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19). Bessalah S, Jebahi S, Mejri N, Salhi I, Khorchani T, Hammadi M. 3 Biotech 11 89 (2021)
  8. Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article. Saied AA, Metwally AA, Alobo M, Shah J, Sharun K, Dhama K. Int J Surg 98 106233 (2022)
  9. Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides. Pomplun S. RSC Med Chem 12 197-202 (2020)
  10. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. Kombe Kombe AJ, Zahid A, Mohammed A, Shi R, Jin T. Front Mol Biosci 8 670815 (2021)
  11. The role and uses of antibodies in COVID-19 infections: a living review. Scourfield DO, Reed SG, Quastel M, Alderson J, Bart VMT, Teijeira Crespo A, Jones R, Pring E, Richter FC, Oxford-Cardiff COVID-19 Literature Consortium , Burnell SEA. Oxf Open Immunol 2 iqab003 (2021)
  12. 50 Years of structural immunology. Wilson IA, Stanfield RL. J Biol Chem 296 100745 (2021)
  13. Anti-SARS-CoV-1 and -2 nanobody engineering towards avidity-inspired therapeutics. Obeng EM, Dzuvor CKO, Danquah MK. Nano Today 42 101350 (2022)
  14. The development of neutralizing antibodies against SARS-CoV-2 and their common features. Liu LD, Lian C, Yeap LS, Meng FL. J Mol Cell Biol 12 980-986 (2020)
  15. Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments. Mahmud N, Anik MI, Hossain MK, Khan MI, Uddin S, Ashrafuzzaman M, Rahaman MM. ACS Appl Bio Mater 5 2431-2460 (2022)
  16. Analysis of the molecular mechanism of SARS-CoV-2 antibodies. Jin D, Wei J, Sun J. Biochem Biophys Res Commun 566 45-52 (2021)
  17. Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view. Najmeddin A, Bahrololoumi Shapourabadi M, Behdani M, Dorkoosh F. Biochim Biophys Acta Gen Subj 1865 129974 (2021)
  18. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. Zebardast A, Hosseini P, Hasanzadeh A, Latifi T. Mol Biol Rep 49 647-656 (2022)
  19. The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. Naidoo DB, Chuturgoon AA. Mol Diagn Ther 27 193-226 (2023)
  20. Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update. Bhattacharya M, Chatterjee S, Lee SS, Chakraborty C. Int J Biol Macromol 229 70-80 (2023)
  21. Advanced microscopy technologies enable rapid response to SARS-CoV-2 pandemic. Cortese M, Laketa V. Cell Microbiol 23 e13319 (2021)
  22. Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus. Feng X, Wang H. ACS Pharmacol Transl Sci 6 925-942 (2023)
  23. Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. Huang K, Ying T, Wu Y. Viruses 14 1162 (2022)
  24. Nanotechnology-based approaches in the fight against SARS-CoV-2. Albaz AA, Rafeeq MM, Sain ZM, Almutairi WA, Alamri AS, Aloufi AH, Almalki WH, Tarique M. AIMS Microbiol 7 368-398 (2021)
  25. Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein. Costa CFS, Barbosa AJM, Dias AMGC, Roque ACA. Biotechnol Adv 59 107986 (2022)
  26. Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2. Wang W, Hu Y, Li B, Wang H, Shen J. Biochem Pharmacol 208 115401 (2023)
  27. Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies. Xue JB, Tao SC. Curr Med Sci 41 1065-1074 (2021)
  28. Multi-omics for COVID-19: driving development of therapeutics and vaccines. Guo M, Xiong M, Peng J, Guan T, Su H, Huang Y, Yang CG, Li Y, Boraschi D, Pillaiyar T, Wang G, Yi C, Xu Y, Chen C. Natl Sci Rev 10 nwad161 (2023)
  29. Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons. Rizk SS, Moustafa DM, ElBanna SA, Nour El-Din HT, Attia AS. World J Microbiol Biotechnol 40 209 (2024)
  30. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. Lim HT, Kok BH, Lim CP, Abdul Majeed AB, Leow CY, Leow CH. Biomed Eng Adv 4 100054 (2022)
  31. Single domain antibodies from camelids in the treatment of microbial infections. De Greve H, Fioravanti A. Front Immunol 15 1334829 (2024)

Articles citing this publication (54)



Quick links